Published Studies Related to Cinryze (Human c1-Esterase Inhibitor)
Cinryze (C1-inhibitor) for the treatment of hereditary angioedema. 
Cinryze is a pasteurized, nanofiltered plasma derived concentrate of C1-inhibitor
(pdC1-INH) licensed for the prophylactic treatment of hereditary angioedema. In a
double-blind placebo-controlled crossover trial to evaluate Cinryze as
prophylaxis, the frequency of attacks was halved (6.26 per 12 weeks on Cinryze
versus 12.73 per 12 weeks on placebo)...
Nanofiltered human C1 inhibitor concentrate (Cinryze(R)): in hereditary angioedema. [2011.10.01]
Intravenous nanofiltered human C1 inhibitor (C1-INH NF) concentrate (Cinryze(R)) is used as a direct replacement of deficient levels of plasma C1 inhibitor in patients with hereditary angioedema (HAE). In the EU, C1-INH NF concentrate 1000 U is indicated in the treatment, pre-procedural prevention, and routine prevention of angioedema attacks in adults and adolescents with HAE...
Clinical Trials Related to Cinryze (Human c1-Esterase Inhibitor)
A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase [Completed]
The objectives of the study are to:
1. Evaluate the safety and tolerability of subcutaneously administered CINRYZE with
recombinant human hyaluronidase (rHuPH20) in subjects with hereditary angioedema (HAE)
who previously participated in CINRYZE Study 0624-200 (NCT01095497)
2. Characterize the pharmacokinetics and pharmacodynamics of subcutaneously administered
CINRYZE with rHuPH20
3. Assess the immunogenicity of CINRYZE following subcutaneous (SC) administration of
CINRYZE with rHuPH20
Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks [Completed]
The primary objectives of the study are to evaluate the safety, tolerability, and efficacy
of two doses of CINRYZE with recombinant human hyaluronidase (rHuPH20) administered by
subcutaneous (SC) injection to prevent angioedema attacks.
CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>85% Organs [Not yet recruiting]
Limiting brain death-induced organ injury through a systemic anti- inflammatory medical
management should allow for improvement in the quality of transplanted organs, and as a
result, clinical improvement in post-transplant outcomes represented by a decrease in the
incidence of delayed graft function (DGF) after transplantation.
The specifc aim is to evaluate the effect of C1INH (CINRYZE) as a donor pre-treatment
strategy to decrease systemic inflammation and decrease the incidence of DGF in Expanded
Criteria Donors (ECD), currently identified as donors with Kidney Donor Profile Index (KDPI)
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12 [Completed]
The objectives of this study were to evaluate: (1) the dose response and (2) the
pharmacokinetics (PK) and pharmacodynamics (PD) of intravenous (IV) administration of
CINRYZE for the treatment of acute angioedema attacks in children above and below 25 kg and
less than 12 years of age with hereditary angioedema (HAE); and (3) to determine the safety
and tolerability following IV administration of CINRYZE in this study population.
Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema [Recruiting]
Primary Objective - To assess the relative efficacy of two dose levels of CINRYZE (500 Units
and 1000 Units) administered by intravenous (IV) injection every 3 or 4 days to prevent
angioedema attacks in children 6 to 11 years of age with hereditary angioedema (HAE).
Secondary Objectives - To assess the safety and tolerability, characterize the
pharmacokinetics (PK) and pharmacodynamics (PD), and assess the immunogenicity of two dose
levels of CINRYZE administered by IV injection in children 6 to 11 years of age with HAE.
Reports of Suspected Cinryze (Human c1-Esterase Inhibitor) Side Effects
Hereditary Angioedema (109),
Inappropriate Schedule of Drug Administration (40),
Device Related Infection (32),
OFF Label USE (26),
Infusion Related Reaction (22),
Drug Dose Omission (17),
Maternal Exposure During Pregnancy (16), more >>